Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tobramycin inhalation solution - Novartis

Next Previous
X
Search
Drug Profile

Tobramycin inhalation solution - Novartis

Alternative Names: TOBI; TOBI NextGen; TOBI® solution; Tobramycin aerosol - Chiron

Latest Information Update: 23 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Aminoglycosides; Anti-infectives; Antibacterials; Antibronchitics; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • No development reported Ventilator associated pneumonia
  • Discontinued Bronchiectasis; Respiratory tract infections; Tuberculosis

Most Recent Events

  • 20 Sep 2019 No development reported - Phase-II for Ventilator-associated-pneumonia in Germany (Inhalation)
  • 31 Aug 2018 Tobramycin inhalation solution market licensed to Mylan worldwide
  • 31 Jul 2017 Discontinued - Phase-III for Cystic fibrosis-associated respiratory tract infections (In infants, In children) in Romania, Egypt, Poland, Italy, Germany, Greece, France, Russia, Switzerland, Hungary and Canada (Inhalation), because not listed on Novartis pipeline, December 2016

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top